SAGE Therapeutics (SAGE) said late Friday that Biogen (BIIB) had submitted an unsolicited, nonbinding proposal to acquire all outstanding shares of the company not already owned for $7.22 per share.
After consulting with its financial and legal advisors, the company said it would review and determine the best course of action for the company and its shareholders.
SAGE Therapeutics' share rose 38% in premarket trading activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.